LDX · ASX

Lumos Diagnostics Holdings Ltd. (ASX:LDX)

AU$0.027

 0.001 (3.846%)
ASX:Live
09/05/2025 02:49:25 PM
HALO Ords HALO Consensus Value GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

LDX Overview

LDX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About LDX

Website

N/A

Telephone

61.3.9087.1598

Address

Level 4 100 Albert Road South Melbourne, Victoria (VIC) 3205

Description

Lumos Diagnostics Holdings Ltd. engages in the development and manufacture of point-of-care diagnostics solutions to help healthcare professionals more accurately diagnose and manage medical conditions. It manages the provision of diagnostics goods and services. It operates through the United States and Australia geographical segments. The company was founded in 2015 and is headquartered in South Melbourne, Australia.

LDX Price Chart

Key Stats

Market Cap

AU$19.46M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.02 - 0.05

Trade Value (12mth)

AU$24,006.00

1 week

-7.14%

1 month

23.81%

YTD

-31.58%

1 year

-44.58%

All time high

1.31

Key Fundamentals

EPS 3 yr Growth

-77.20%

EBITDA Margin

-45.00%

Operating Cashflow

$1m

Free Cash Flow Return

6.10%

ROIC

-55.60%

Interest Coverage

-4.90

Quick Ratio

0.70

Other Data

Shares on Issue (Fully Dilluted)

613m

HALO Sector

Healthcare

Next Company Report Date

26-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

LDX Announcements

Latest Announcements

Date Announcements

06 May 25

Q3 FY25 Investor Briefing

×

Q3 FY25 Investor Briefing

29 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

23 April 25

Lumos Secures Further US Medicare Reimbursement for FebriDx

×

Lumos Secures Further US Medicare Reimbursement for FebriDx

17 April 25

Lumos Secures Key US Reimbursement Milestones for FebriDx

×

Lumos Secures Key US Reimbursement Milestones for FebriDx

14 April 25

Notification of cessation of securities - LDX

×

Notification of cessation of securities - LDX

02 April 25

Investor Presentation

×

Investor Presentation

24 March 25

Investor Information Session Invitation

×

Investor Information Session Invitation

03 March 25

Hologic Development Agreement Expanded Scope of Works

×

Hologic Development Agreement Expanded Scope of Works

03 March 25

1H FY25 Results Investor Briefing

×

1H FY25 Results Investor Briefing

27 February 25

Appendix 4D and Half Year Report

×

Appendix 4D and Half Year Report

25 February 25

1H FY25 Results Investor Briefing Invitation

×

1H FY25 Results Investor Briefing Invitation

05 February 25

Q2 FY25 Results Investor Briefing Invitation

×

Q2 FY25 Results Investor Briefing Invitation

31 January 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

13 January 25

Lumos Partners with MedPro for Sales of FebriDx in the US

×

Lumos Partners with MedPro for Sales of FebriDx in the US

13 January 25

Notification of cessation of securities - LDX

×

Notification of cessation of securities - LDX

09 January 25

Notification of cessation of securities - LDX

×

Notification of cessation of securities - LDX

20 December 24

Section 708A Cleansing Statement

×

Section 708A Cleansing Statement

20 December 24

Application for quotation of securities - LDX

×

Application for quotation of securities - LDX

20 December 24

Listing Rule 6.22.2 Adjustment to Option Exercise Prices

×

Listing Rule 6.22.2 Adjustment to Option Exercise Prices

19 December 24

Commencement of FebriDx CLIA Waiver Study

×

Commencement of FebriDx CLIA Waiver Study

13 December 24

Notification regarding unquoted securities - LDX

×

Notification regarding unquoted securities - LDX

10 December 24

Change of Director's Interest Notice - DW

×

Change of Director's Interest Notice - DW

06 December 24

Section 708A Cleansing Statement

×

Section 708A Cleansing Statement

06 December 24

Application for quotation of securities - LDX

×

Application for quotation of securities - LDX

05 December 24

Lumos receives CPT PLA Code for FebriDX in the US

×

Lumos receives CPT PLA Code for FebriDX in the US

LDX Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.39 -0.05 -0.03 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.39 -0.05 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -232.2 86.3 50.1 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.09 -0.03 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.17 -0.06 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -3.2 72.1 48.4 Lock Lock Lock
     Yield % Lock Lock Lock Lock -132.9 -561.9 9.5 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.12 0.04 0.02 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.03 -0.01 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock -86.1 -118.2 -18.5 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 162 250 494 Lock Lock Lock
Basic m Lock Lock Lock Lock 162 250 494 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 16 16 17 Lock Lock Lock
     Growth % Lock Lock Lock Lock -36.6 -2.3 8.5 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 17 8 5 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -12 -6 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -1,461.4 44.4 15.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -72.1 -41.1 -32.1 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 172 141 132 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -30 -10 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock -108.9 67.4 21.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -185.0 -61.7 -45.0 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 4 5 4 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -34 -15 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock -127.6 54.9 22.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -209.3 -96.6 -68.8 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -63 -13 -13 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -63 -13 -13 Lock Lock Lock
     Growth % Lock Lock Lock Lock -212.9 78.8 1.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -393.2 -85.2 -77.2 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -25 -14 1 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 6 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -6 6 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock -15 1 4 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -28 -15 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.1 48.8 109.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1.8 -0.9 0.1 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 12 5 10 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 54 38 40 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 9 12 11 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -1 10 2 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 28 24 30 Lock Lock Lock
Equity $m Lock Lock Lock Lock 26 14 11 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 35 26 21 Lock Lock Lock
     Growth % Lock Lock Lock Lock -59.8 -26.1 -17.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -117.4 -34.9 -32.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -242.4 -93.5 -123.2 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -53.8 -46.2 -45.2 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -103.1 -43.7 -55.6 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -40.6 -47.0 6.1 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -35.3 -2.7 -4.9 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 0.0 -1.1 -0.3 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -4.4 71.3 22.2 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 1.0 0.7 0.8 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 0.9 0.6 0.7 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 59.4 50.6 67.8 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -133.3 -116.7 7.6 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 3.8 6.3 7.1 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 5.6 8.4 16.2 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 18.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 13.2 10.9 4.8 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.3 0.4 0.4 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.3 0.4 0.4 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -393.2 -85.2 -77.2 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -117.4 -34.9 -32.6 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -117.4 -34.9 -32.6 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 2.1 2.7 3.8 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -242.4 -93.5 -123.2 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -242.4 -93.5 -123.2 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 64.7 43.5 22.5 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 95.7 58.1 51.1 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 160.4 101.6 73.6 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 59.3 34.8 20.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 101.1 66.8 52.7 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

-0.10%

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

LDX Shortsell

Frequently Asked Questions

The current share price of Lumos Diagnostics Holdings Ltd. (LDX:ASX) is AU$0.027.
The 52-week high share price for Lumos Diagnostics Holdings Ltd. (LDX:ASX) is AU$0.05.
The 52-week low share price for Lumos Diagnostics Holdings Ltd. (LDX:ASX)? is AU$0.02.
Lumos Diagnostics Holdings Ltd. (LDX:ASX) does not pay a dividend.
Lumos Diagnostics Holdings Ltd. (LDX:ASX) does not pay a dividend.
Lumos Diagnostics Holdings Ltd. (LDX:ASX) has a franking level of 0.0%.
Lumos Diagnostics Holdings Ltd. (LDX:ASX) is classified in the Healthcare.
The current P/E ratio for Lumos Diagnostics Holdings Ltd. (LDX:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.